Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Giacomo Sgalla, Elisabetta Cocconcelli, Roberto Tonelli & Luca Richeldi. (2016) Novel drug targets for idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine 10:4, pages 393-405.
Read now
Read now
Yoshito Takeda, Kazuyuki Tsujino, Takashi Kijima & Atsushi Kumanogoh. (2014) Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Preference and Adherence 8, pages 361-370.
Read now
Read now
Hai-Jing Zhang, Wen-Yang Han, Shan-Ying Peng, Yang Liu, Lian-Qiu Wu & Wen-Jie Wang. (2014) The inhibition effect and mechanism of SY0916 on pulmonary fibrosis. Journal of Asian Natural Products Research 16:6, pages 658-666.
Read now
Read now
Articles from other publishers (16)
Nikitha Naomi Dsouza, Varun Alampady, Krishnaprasad Baby, Swastika Maity, Bharath Harohalli Byregowda & Yogendra Nayak. (2023) Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis. Inflammopharmacology 31:3, pages 1167-1182.
Crossref
Crossref
Francesco Ferrara, Giovanni Granata, Chiara Pelliccia, Raffaele La Porta & Antonio Vitiello. (2020) The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2. European Journal of Clinical Pharmacology 76:11, pages 1615-1618.
Crossref
Crossref
John Varga & Fredrick M. Wigley. 2019. Clinical Immunology. Clinical Immunology
743
755.e1
.
Ana Catarina Duarte, Maria José Santos & Ana Cordeiro. (2017) Anti-fibrotic nintedanib—a new opportunity for systemic sclerosis patients?. Clinical Rheumatology 37:4, pages 1123-1127.
Crossref
Crossref
Ferran Morell, Dirk Esser, Jonathan Lim, Susanne Stowasser, Alba Villacampa, Diana Nieves & Max Brosa. (2016) Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain – results of a Delphi Panel. BMC Pulmonary Medicine 16:1.
Crossref
Crossref
Tong Sun, Jing Liu & De Wei Zhao. (2016) Efficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis. Medicine 95:19, pages e3629.
Crossref
Crossref
G. Cusumano, J. Romagnoli, G. Liuzzo, L.P. Ciavarella, A. Severino, G. Copponi, M. Manchi, S. Giubilato, G.F. Zannoni, E. Stigliano, M.E. Caristo, F. Crea & F. Citterio. (2015) N-Acetylcysteine and High-Dose Atorvastatin Reduce Oxidative Stress in an Ischemia-Reperfusion Model in the Rat Kidney. Transplantation Proceedings 47:9, pages 2757-2762.
Crossref
Crossref
Signe Vedel-Krogh, Sune F. Nielsen & Børge G. Nordestgaard. (2015) Statin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease. PLOS ONE 10:10, pages e0140571.
Crossref
Crossref
Thomas G. O'Riordan, Victoria Smith & Ganesh Raghu. (2015) Development of Novel Agents for Idiopathic Pulmonary Fibrosis. Chest 148:4, pages 1083-1092.
Crossref
Crossref
Brian S. Comer, Mariam Ba, Cherie A. Singer & William T. Gerthoffer. (2015) Epigenetic targets for novel therapies of lung diseases. Pharmacology & Therapeutics 147, pages 91-110.
Crossref
Crossref
Mario C. Manresa, Catherine Godson & Cormac T. Taylor. (2014) Hypoxia-sensitive pathways in inflammation-driven fibrosis. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 307:12, pages R1369-R1380.
Crossref
Crossref
Keith C Meyer. (2014) Diagnosis and management of interstitial lung disease. Translational Respiratory Medicine 2:1.
Crossref
Crossref
Guillermo Avila, Diana Stephanie Osornio-Garduño, Erick Benjamín Ríos-Pérez & Roberto Ramos-Mondragón. (2014) Functional and structural impact of pirfenidone on the alterations of cardiac disease and diabetes mellitus. Cell Calcium 56:5, pages 428-435.
Crossref
Crossref
David Lu & Paul A. Insel. (2014) Cellular Mechanisms of Tissue Fibrosis. 6. Purinergic signaling and response in fibroblasts and tissue fibrosis. American Journal of Physiology-Cell Physiology 306:9, pages C779-C788.
Crossref
Crossref
Vincent Cottin, M Wijsenbeek, F Bonella & C Vancheri. (2014) Slowing progression of idiopathic pulmonary fibrosis with pirfenidone: from clinical trials to real-life experience. Clinical Investigation 4:4, pages 313-326.
Crossref
Crossref
Gordon F. Rushworth & Ian L. Megson. (2014) Existing and potential therapeutic uses for N-acetylcysteine: The need for conversion to intracellular glutathione for antioxidant benefits. Pharmacology & Therapeutics 141:2, pages 150-159.
Crossref
Crossref